[ad_1]
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
(Reuters) – Gene and cell therapy firm Oxford Biomedica said on Monday it signed a new manufacturing agreement to help it scale up production of AstraZeneca’s potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.
Oxford Biomedica, which last week appointed a new chair as it vies for a bigger role in vaccine manufacturing, said the five-year partnership with the UK’s Vaccines Manufacturing and Innovation Centre (VMIC) would also help it make other viral vector vaccines.
Reporting by Pushkala Aripaka in Bengaluru; editing by Uttaresh.V
[ad_2]
Source link